Medifacts announces USD 6.2m study award

Medifacts International, a US-based provider of non-invasive cardiac safety services, has signed a four-year global study worth approximately USD 6.2m.

The study is a late state registration programme sponsored by a major, but presently unnamed, biotechnology company.

Medifacts will provide comprehensive support for ECG, Holter, as well as ABPM endpoints including provision of equipment for digital collection of cardiac safety data that will be transferred to Medifacts for processing and analysis.

The company will use its proprietary web-based platform, WebHeart, which will enable efficient management of the data and provide a fully-digital environment for manual measurement and overread of ECGs and other cardiac safety and efficacy data while exceeding regulatory guidance and technical standards.

Michael Woehler, Medifacts' CEO, said: "The award represents an endorsement of the tremendous quality of our global services and a continuing vote of long-term confidence in the company by the sponsor community. Our WebHeart platform continues to set the global standard in cardiac safety data collection, management and submission, and we continue to consolidate our position as one of the top five global cardiac safety businesses.î